{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:29:33Z","timestamp":1782959373729,"version":"3.54.5"},"reference-count":20,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an aggressive central nervous system astrocytopathy often resulting in rapid neurologic decline. Patients have recurrent flares that require immunomodulatory therapy for relapse prevention. These patients are usually hospitalized and may need rehospitalization after decline. Hospital readmission rates are important indicators that can be used to gauge health care quality and have direct implications on hospital compensation. This study aims to identify high-risk characteristics of patients with NMOSD that can be used to predict hospital readmissions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The 2017 Nationwide Readmissions Database was searched for hospital admissions for NMOSD in the United States. All patients with hospital readmission within 30 days of discharge from the index hospitalization were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The 30-day all-cause readmission rate for NMOSD was 11.9% (95% CI, 10.6%-13.3%). Patients aged 65 to 74 years had higher odds of readmission; those with private insurance had decreased odds. Sex did not affect readmission. Several comorbidities, such as respiratory failure, peripheral vascular disease, neurocognitive disorders, and neurologic blindness, were predictive of readmissions. Plasma exchange increased the odds of readmission, whereas intravenous immunoglobulin and immunomodulatory infusions, such as chemotherapies and monoclonal antibodies, did not affect readmission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The most common etiologies for 30-day read-mission were neurologic, infectious, and respiratory. Treatment targeted toward these etiologies may result in reduced overall readmission, thereby decreasing overall disease burden.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2022-049","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T22:35:46Z","timestamp":1687559746000},"page":"221-225","source":"Crossref","is-referenced-by-count":4,"title":["Hospital Readmission Rates in Patients With Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.7224","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-7727","authenticated-orcid":true,"given":"Akhil","family":"Padarti","sequence":"first","affiliation":[{"name":"From the Department of Neurology, Mobile, AL, USA (AP, WK)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod","family":"Amritphale","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (AA), University of South Alabama College of Medicine, Mobile, AL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kilgo","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Mobile, AL, USA (AP, WK)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2024020703113145200_i1537-2073-25-5-221-b1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"6","key":"2024020703113145200_i1537-2073-25-5-221-b2","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms22062801","article-title":"Neuromyelitis optica spectrum disorder treatment: current and future prospects","volume":"22","author":"Waliszewska-Pros\u00f3\u0142","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2024020703113145200_i1537-2073-25-5-221-b3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"2024020703113145200_i1537-2073-25-5-221-b4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fneur.2020.00537","article-title":"Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","volume":"11","author":"Khalilidehkordi","year":"2020","journal-title":"Front Neurol"},{"key":"2024020703113145200_i1537-2073-25-5-221-b5","doi-asserted-by":"crossref","first-page":"100134","DOI":"10.1016\/j.nerep.2022.100134","article-title":"Neuromyelitis optica spectrum disorder relapse during the third trimester of pregnancy","volume":"2","author":"Tallavajhala","year":"2022","journal-title":"Neuroimmunol Rep"},{"issue":"8","key":"2024020703113145200_i1537-2073-25-5-221-b6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/1352458516674366","article-title":"Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G","volume":"23","author":"Kim","year":"2017","journal-title":"Mult Scler"},{"issue":"22","key":"2024020703113145200_i1537-2073-25-5-221-b7","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"key":"2024020703113145200_i1537-2073-25-5-221-b8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"2024020703113145200_i1537-2073-25-5-221-b9","doi-asserted-by":"publisher","first-page":"46958019860386","DOI":"10.1177\/0046958019860386","article-title":"Readmission rates and their impact on hospital financial performance: a study of Washington hospitals","volume":"56","author":"Upadhyay","year":"2019","journal-title":"Inquiry"},{"issue":"5","key":"2024020703113145200_i1537-2073-25-5-221-b10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7224\/1537-2073.2021-089","article-title":"Readmission rates in patients with multiple sclerosis: a nationwide cohort study","volume":"24","author":"Padarti","year":"2022","journal-title":"Int J MS Care"},{"key":"2024020703113145200_i1537-2073-25-5-221-b11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.msard.2019.03.012","article-title":"Thirty-day readmissions in multiple sclerosis: an age and gender-based US national retrospective analysis","volume":"31","author":"Patel","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2024020703113145200_i1537-2073-25-5-221-b12","article-title":"Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality, Department of Health and Human Services","author":"NRD Database Documentation","year":"2022","journal-title":"Last modified"},{"key":"2024020703113145200_i1537-2073-25-5-221-b13","doi-asserted-by":"publisher","first-page":"652759","DOI":"10.3389\/fphar.2021.652759","article-title":"Monoclonal antibody therapy in neuromyelitis optica spectrum disorders: a meta-analysis of randomized control trials","volume":"12","author":"Kong","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024020703113145200_i1537-2073-25-5-221-b14","doi-asserted-by":"publisher","DOI":"10.23736\/S0390-5616.21.05605-8","article-title":"Readmissions in patients with cerebral cavernous malformations (CCMs): a National Readmission Database (NRD) study","author":"Padarti","journal-title":"J Neurosurg Sci"},{"key":"2024020703113145200_i1537-2073-25-5-221-b15","volume-title":"Characteristics of 30-day all-cause hospital readmissions, 2010-2016: statistical brief #248","author":"Bailey","year":"2019"},{"issue":"7","key":"2024020703113145200_i1537-2073-25-5-221-b16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"key":"2024020703113145200_i1537-2073-25-5-221-b17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","article-title":"Oxidative stress in multiple sclerosis: central and peripheral mode of action","volume":"277","author":"Ohl","year":"2016","journal-title":"Exp Neurol"},{"issue":"2","key":"2024020703113145200_i1537-2073-25-5-221-b18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1352458516650512","article-title":"Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course","volume":"23","author":"Conway","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"2024020703113145200_i1537-2073-25-5-221-b19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"2024020703113145200_i1537-2073-25-5-221-b20","doi-asserted-by":"publisher","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front Neurol"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/25\/5\/221\/3325259\/i1537-2073-25-5-221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/25\/5\/221\/3325259\/i1537-2073-25-5-221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:16Z","timestamp":1752786796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/hospital-readmission-rates-in-patients-with-neuromyelitis-optica-spectrum-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,14]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2022-049","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}